There is evidence to suggest that most of the increase in GAG synthesis is in the hyaluronic acid fraction. 34 Methotrexate in low doses is efficacious in treating several connective tissue diseases, such as rheumatoid arthritis (RA),5 6 dermatomyositis, and polymyositis.7 Low doses of methotrexate have also been reported to reduce skin thickening in patients with systemic sclerosis. 8 9 The mechanisms through which low doses of methotrexate affect the inflammatory process in rheumatic disease are as yet unknown. Most studies of the immune system in patients with RA who have been treated with low doses of methotrexate show only marginal effects on the humoral and cellular immune responses. The rapid clinical responses to treatment and equally rapid flare up upon discontinuation suggest an antiinflammatory effect.'0 One study suggests that one of the roles of methotrexate in RA may be to inhibit interleukin 1 mediated proliferation of synovial fibroblasts."
This study was undertaken to determine the effects of increasing concentrations of methotrexate on the proliferation of cultured scleroderma skin fibroblasts and their production of GAGs.
Patients and methods

PATIENTS WITH SCLERODERMA AND NORMAL VOLUNTEERS
The nine patients fulfilled the American Rheumatism Association's preliminary criteria for the diagnosis of systemic sclerosis.'2 The mean (SD) age of the patients was 49 4 (8A4) years, with a range of 38-63 years. Seven patients were women and two were men. Five had diffuse systemic sclerosis-that is, with the skin proximal to the elbows affected-and four had limited systemic sclerosis that is, with the skin distal to the elbows affected. Disease duration, estimated from the first signs of skin thickening, varied from six months to seven years, the median being 48 months. In six patients antibodies to topoisomerase I could be detected; in two others anticentromere antibodies were found. None of the patients had previously received any drug treatment known to influence connective tissue metabolism. The control group consisted of nine normal volunteers, five men and four women, with a mean (SD) age of 46-4 (11-7) years (range 29-67 years).
FIBROBLAST EXPLANT CULTURES
Full thickness skin biopsy samples were taken with a 4 mm punch from each patient at a site of dermal thickening on the dorsum of the left forearm; from each donor a biopsy sample was taken from either the dorsal forearm or the upper arm. Each biopsy specimen was minced and placed in a 25 cm2 plastic tissue culture flask (Costar, Cambridge, MA, USA), to which 4 ml nutrient medium was added. The latter consisted of Dulbecco's modified Eagle's medium (DMEM; Flow Laboratories, Irvine, Strathclyde, UK) that contained 0-002 M glutamine and 0-02 M HEPES buffer and had been supplemented with 15% fetal calf serum and gentamycin (40 ,ug/ml; Schering, Kenilworth, NJ, USA). In addition to HEPES buffer the medium pH was controlled by sodium hydrogencarbonate.
Each culture was maintained at 37°C in a humidified atmosphere of a CO2 incubator containing 5% C02 in air. The medium was completely replaced one to three times a week, depending on the change in colour. Once fibroblasts had grown from an explant culture, the old medium was discarded and fibroblasts were dispersed with 1 RI papain (5 mg/ml). The cells and decanted media were incubated at 60°C for 24 hours. A 0-2% solution of cetylpyridinium chloride (CPC) was then added, 400 pA to the fibroblasts and 600 plA to the medium, to obtain a final concentration of 0-1% in all samples. These were incubated at 37°C for one hour to allow the GAG-CPC complex to precipitate.
The resulting pellets were centrifuged and washed, the cell fraction twice and the medium fraction three times, with 0O05/o CPC to remove any remaining glycopeptides and unincorporated precursors. Each pellet was then supplemented with 0 5 ml Luma solve (Lumac.LSC, Olen, Belgium) and, after an incubation of 10 minutes at 60°C, 10 overlap were made. As these experiments were not performed simultaneously, the specific activities of the isotopes had been determined before labelling. The results were corrected for the decrease in radioactivity that occurred during the course of the study to obtain results for the levels of incorporation that could be compared. FIBROBLAST van den Hoogen, van derma fibroblasts in each well was lower than that of control fibroblasts for all concentrations of methotrexate except 1 x 10 2 molI, but the differences were not significant. (fig 2A) . Likewise, the total [35S] count rate was positively correlated with the corresponding concentration of methotrexate ( fig 2B) .
As the extent of skin disease and disease duration in systemic sclerosis may influence GAG synthesis, we compared the results for fibroblast cultures derived from specimens from five patients with diffuse skin disease with those for cultures derived from specimens from four patients with limited skin disease. (8) 76 (8) 75 (7) 81 (7) 83 (5) Normal fibroblasts 75 (6) 77 (8) 74 (7) 77 (9) 80 (7) [35S] medium Scleroderma fibroblasts 65 (11) 62 (7) 59 (8) 60 (11) 62 (11) Normal fibroblasts 57 (9) 58 (12) 56 (12) 57 (13) 62 (15) disease, but the differences were significant for a methotrexate concentration of The results obtained in this study are inconsistent with the reported beneficial effect of low doses of methotrexate of the skin in systemic sclerosis. Therefore any beneficial effect of methotrexate on skin thickening in systemic sclerosis is most probably not the result of direct inhibition of GAG production by fibroblasts, but is more likely to be based on modulation of the (immuno)inflammatory system. 
